Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Monoclonal Antibodies in Colorectal Cancer Market to 2019 – Introduction 9
2.1 Symptoms 9
2.2 Etiology 9
2.3 Epidemiology 10
2.4 Pathophysiology 11
2.5 Diagnosis 11
2.6 Prognosis and Disease Staging 12
2.7 Treatment Options 13
2.7.1 Chemotherapy 13
2.7.2 Targeted Therapies 14
2.7.3 Resistance to Pharmacological Therapies 15
2.7.4 Treatment Guidelines 15
3 Monoclonal Antibodies in Colorectal Cancer Market to 2019 – Marketed Products 18
3.1 Avastin (Bevacizumab) – Hoffman La Roche 18
3.2 Erbitux (Cetuximab) – Bristol-Myers Squibb, Eli Lilly, and Merck KGaA 19
3.3 Vectibix (Panitumumab) – Amgen and Takeda 21
3.4 Heat Map for Marketed Products 22
3.5 Conclusion 24
4 Monoclonal Antibodies in Colorectal Cancer Market to 2019 – Developmental Pipeline 25
4.1 Overall Pipeline 25
4.2 Molecular Targets and Mechanisms of Action 27
4.3 Clinical Trials 28
4.3.1 Failure Rate 28
4.3.2 Clinical Trial Size 29
4.3.3 Duration 32
4.3.4 Primary Endpoints 33
4.4 Conclusion 35
4.5 Key Late-Stage Pipeline Products 35
4.5.1 IMC-1121B (Ramucirumab) – Eli Lilly and Company 35
4.5.2 Xilonix – XBiotech 36
4.5.3 MetMAb (Onartuzumab) – Hoffmann-La Roche 36
4.5.4 Anti-DR5 MoAb (Tigatuzumab) – Daiichi Sankyo 36
4.5.5 MK0646 (Dalotuzumab) – Merck 37
4.5.6 AMG-655 (Conatumumab) – Amgen 37
4.6 Conclusion 37
5 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Market Forecast to 2019 38
5.1 Global 39
5.1.1 Treatment Usage Patterns 39
5.1.2 Market Size 40
5.2 North America 41
5.2.1 US 41
5.2.2 Canada 43
5.3 Europe 44
5.3.1 Treatment Usage Patterns 44
5.3.2 Annual Cost of Therapy 45
5.3.3 Market Size 47
5.4 Japan 48
5.4.1 Treatment Usage Patterns 48
5.4.2 Market Size 49
5.5 Drivers and Barriers 49
5.5.1 Drivers 49
5.5.2 Barriers 50
6 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Deals and Strategic Consolidations 52
6.1 R&D Licensing Agreements 52
6.1.1 Key Licensing Deals 55
6.2 Co-Development Agreements 57
6.2.1 Key Co-Development Agreements 58
7 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Appendix 59
7.1 Market Definitions 59
7.2 Abbreviations 59
7.3 References 62
7.4 Sources for Heat Map 66
7.5 All Pipeline Products, by Stage of Development 67
7.5.1 Discovery 67
7.5.2 Preclinical and IND/CTA-filed 68
7.5.3 Phase I 73
7.5.4 Phase II 76
7.5.5 Phase III and Pre-registration 81
7.5.6 Undisclosed 82
7.6 Tabular Forecast Data 83
7.6.1 Global 83
7.6.2 US 83
7.6.3 Canada 83
7.6.4 UK 83
7.6.5 France 84
7.6.6 Germany 84
7.6.7 Italy 84
7.6.8 Spain 84
7.6.9 Japan 85
7.7 Research Methodology 85
7.7.1 Coverage 85
7.7.2 Secondary Research 85
7.7.3 Primary Research 86
7.7.4 Therapeutic Landscape 86
7.7.5 Epidemiology-Based Forecasting 86
7.7.6 Market Size by Geography 88
7.7.7 Geographical Landscape 89
7.7.8 Pipeline Analysis 89
7.8 Contact Us 89
7.9 Disclaimer 89